Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Diabetes

  Free Subscription


Articles published in Ann Intern Med

Retrieve available abstracts of 94 articles:
HTML format



Single Articles


    July 2020
  1. DOUROS A, Lix LM, Fralick M, Dell'Aniello S, et al
    Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis: A Multicenter Cohort Study.
    Ann Intern Med. 2020 Jul 28. doi: 10.7326/M20-0289.
    PubMed     Abstract available


    June 2020
  2. LEE CG, Cefalu WT
    The Right Diabetes Medication for the Right Patient for the Right Outcome: Can a Network Meta-analysis Help Us Decide?
    Ann Intern Med. 2020 Jun 30. doi: 10.7326/M20-4266.
    PubMed    


  3. TSAPAS A, Avgerinos I, Karagiannis T, Malandris K, et al
    Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
    Ann Intern Med. 2020 Jun 30. doi: 10.7326/M20-0864.
    PubMed     Abstract available


    May 2020
  4. TIAN S, Wu J, Liu JS, Zou BS, et al
    Type 2 Diabetes.
    Ann Intern Med. 2020;172:704-705.
    PubMed    


  5. VIJAN S
    Type 2 Diabetes.
    Ann Intern Med. 2020;172:705.
    PubMed    



  6. Correction: In the Clinic: Type 2 Diabetes.
    Ann Intern Med. 2020;172:708.
    PubMed    


    April 2020
  7. TANNER M
    In screen-detected type 2 diabetes, intensive therapy did not differ from usual care for CV events at 10 years.
    Ann Intern Med. 2020;172:JC41.
    PubMed    


    March 2020
  8. KLOECKER DE, Davies MJ, Khunti K, Zaccardi F, et al
    Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes.
    Ann Intern Med. 2020 Mar 24. pii: 2763641. doi: 10.7326/M19-3286.
    PubMed     Abstract available


  9. LIAKOS A, Liakopoulou P, Tsapas A
    Cyclical pressurized topical wound oxygen therapy increased healing of refractory diabetic foot ulcers.
    Ann Intern Med. 2020;172:JC27.
    PubMed    


    February 2020
  10. BROWN K, Donato AA
    In type 2 diabetes, early metformin plus vildagliptin reduced treatment failure vs a stepwise approach.
    Ann Intern Med. 2020;172:JC23.
    PubMed    


  11. AI NG SY, Zhu D, Herrington WG
    In type 2 diabetes, SGLT-2 inhibitors reduce risk for major kidney outcomes.
    Ann Intern Med. 2020;172:JC18.
    PubMed    


    January 2020
  12. RACO DL
    In stable CAD with type 2 diabetes, adding ticagrelor to aspirin reduced CV events but increased major bleeding.
    Ann Intern Med. 2020;172:JC4.
    PubMed    


  13. FRALICK M, Chen SK, Patorno E, Kim SC, et al
    Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study.
    Ann Intern Med. 2020 Jan 14. pii: 2758844. doi: 10.7326/M19-2610.
    PubMed     Abstract available


    December 2019
  14. DAVE CV, Schneeweiss S, Kim D, Fralick M, et al
    Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections.
    Ann Intern Med. 2019;171:944-945.
    PubMed    


  15. SARAFIDIS P, Papagianni A
    Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections.
    Ann Intern Med. 2019;171:943-944.
    PubMed    


  16. BENJAMIN T, Schumacher C
    Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections.
    Ann Intern Med. 2019;171:944.
    PubMed    


  17. CENTOR RM, Ovalle F
    Web Exclusive. Annals On Call - Technology to Improve Diabetes Management.
    Ann Intern Med. 2019;171:OC1.
    PubMed    


    November 2019
  18. VIJAN S
    Type 2 Diabetes.
    Ann Intern Med. 2019;171:ITC65-ITC80.
    PubMed     Abstract available


    October 2019
  19. MOIST L
    Dapagliflozin reduced cardiorenal outcomes but not MACE in T2 diabetes with or at risk for atherosclerotic CVD.
    Ann Intern Med. 2019;171:JC43.
    PubMed    


  20. SMETANA GW, Nathan DM, Dugdale DC, Burns RB, et al
    To What Target Hemoglobin A1c Level Would You Treat This Patient With Type 2 Diabetes?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
    Ann Intern Med. 2019;171:505-513.
    PubMed     Abstract available


    September 2019
  21. SANTULLI G
    In type 2 diabetes, intensive glucose control for 5.6 years did not differ from usual care for major CV events at 14 years.
    Ann Intern Med. 2019;171:JC31.
    PubMed    


  22. EL KAWKGI OM, Montori VM
    In high-risk type 1 diabetes, insulin pumps with suspend-before-low technology reduced hypoglycemic events.
    Ann Intern Med. 2019;171:JC30.
    PubMed    


  23. LIPSCOMBE LL
    In poorly controlled type 2 diabetes, oral semaglutide was noninferior to liraglutide for reducing HbA1c.
    Ann Intern Med. 2019;171:JC29.
    PubMed    


  24. LIPSCOMBE LL
    In patients >/= 50 years with type 2 diabetes and CV disease or risk factors, oral semaglutide did not increase CV events.
    Ann Intern Med. 2019;171:JC28.
    PubMed    


  25. LIPSCOMBE LL
    In patients >/= 50 years with type 2 diabetes and CV disease or risk factors, dulaglutide reduced CV outcomes.
    Ann Intern Med. 2019;171:JC27.
    PubMed    


    August 2019
  26. GOEL A
    In type 2 diabetes, a primary care-led weight management program increased weight loss and diabetes remission at 2 years.
    Ann Intern Med. 2019;171:JC17.
    PubMed    


  27. LIPSCOMBE LL
    In uncontrolled type 2 diabetes, adjunctive semaglutide reduced HbA1c and body weight vs sitagliptin.
    Ann Intern Med. 2019;171:JC16.
    PubMed    


  28. PATEL T
    Canagliflozin reduced kidney failure and CV events at 2.6 years in type 2 diabetes with chronic kidney disease.
    Ann Intern Med. 2019;171:JC15.
    PubMed    


  29. CHAMBERLAIN JJ, Doyle-Delgado K, Peterson L, Skolnik N, et al
    Diabetes Technology: Review of the 2019 American Diabetes Association Standards of Medical Care in Diabetes.
    Ann Intern Med. 2019 Aug 13. pii: 2748278. doi: 10.7326/M19-1638.
    PubMed     Abstract available


  30. WHARAM JF, Newhouse JP
    High-Deductible Insurance and Delay in Care.
    Ann Intern Med. 2019;171:226.
    PubMed    


  31. GOULET M, Goldstein J
    High-Deductible Insurance and Delay in Care.
    Ann Intern Med. 2019;171:226.
    PubMed    


    July 2019
  32. FILION KB, Yu OH
    Sodium-Glucose Cotransporter-2 Inhibitors and Severe Urinary Tract Infections: Reassuring Real-World Evidence.
    Ann Intern Med. 2019 Jul 30. pii: 2739787. doi: 10.7326/M19-1950.
    PubMed    


  33. JACKSON GL, Smith VA, Edelman D, Hendrix CC, et al
    Intermediate Diabetes Outcomes in Patients Managed by Physicians, Nurse Practitioners, or Physician Assistants.
    Ann Intern Med. 2019;171:145.
    PubMed    


  34. KUMAR PD
    Intermediate Diabetes Outcomes in Patients Managed by Physicians, Nurse Practitioners, or Physician Assistants.
    Ann Intern Med. 2019;171:144.
    PubMed    


  35. GROTE J
    Intermediate Diabetes Outcomes in Patients Managed by Physicians, Nurse Practitioners, or Physician Assistants.
    Ann Intern Med. 2019;171:144-145.
    PubMed    


  36. KE C, Shah BR, Stukel TA, Chan JCN, et al
    Excess Burden of Mental Illness and Hospitalization in Young-Onset Type 2 Diabetes.
    Ann Intern Med. 2019;171:78-79.
    PubMed    


  37. FINUCANE TE
    Excess Burden of Mental Illness and Hospitalization in Young-Onset Type 2 Diabetes.
    Ann Intern Med. 2019;171:78.
    PubMed    


    May 2019
  38. MERLI GJ, Weitz HH
    Web Exclusive. Annals Consult Guys - Cardiovascular Risk, Blood Pressure, and Cognition in a Patient With Diabetes.
    Ann Intern Med. 2019;170:CG1.
    PubMed    


  39. GOEL A
    Review: Viscous fiber reduces HbA1c, fasting glucose, and insulin resistance in type 2 diabetes.
    Ann Intern Med. 2019;170:JC51.
    PubMed    


    April 2019
  40. LUDVIGSSON JF, Neovius M, Soderling J, Gudbjornsdottir S, et al
    Maternal Glycemic Control in Type 1 Diabetes and the Risk for Preterm Birth: A Population-Based Cohort Study.
    Ann Intern Med. 2019 Apr 23. pii: 2731602. doi: 10.7326/M18-1974.
    PubMed     Abstract available


  41. APOLZAN JW, Venditti EM, Edelstein SL, Knowler WC, et al
    Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study.
    Ann Intern Med. 2019 Apr 23. pii: 2731601. doi: 10.7326/M18-1605.
    PubMed     Abstract available


  42. KANSAGARA D, Humphrey LL, Qaseem A
    World Health Organization Guidelines on Medicines for Diabetes Treatment Intensification.
    Ann Intern Med. 2019;170:583-584.
    PubMed    


  43. GOOD CB, Kolb NR, Meyer M
    World Health Organization Guidelines on Medicines for Diabetes Treatment Intensification.
    Ann Intern Med. 2019;170:583.
    PubMed    


  44. PUNTHAKEE Z
    In type 2 diabetes with periodontitis, intensive periodontitis treatment improved glycemic control at 1 year.
    Ann Intern Med. 2019;170:JC40.
    PubMed    


  45. DAVIDSON MB
    Review: Rapid-acting analogues do not differ from regular human insulin for mortality or HbA1c in type 2 diabetes.
    Ann Intern Med. 2019;170:JC39.
    PubMed    


  46. ARTERBURN D
    Microvascular Outcomes in Patients With Diabetes After Bariatric Surgery.
    Ann Intern Med. 2019;170:507-508.
    PubMed    


  47. KWON Y, Park S
    Microvascular Outcomes in Patients With Diabetes After Bariatric Surgery.
    Ann Intern Med. 2019;170:507.
    PubMed    


  48. CARLSSON L, Carlsson B, Peltonen M
    Microvascular Outcomes in Patients With Diabetes After Bariatric Surgery.
    Ann Intern Med. 2019;170:506-507.
    PubMed    


    January 2019
  49. KE C, Lau E, Shah BR, Stukel TA, et al
    Excess Burden of Mental Illness and Hospitalization in Young-Onset Type 2 Diabetes: A Population-Based Cohort Study.
    Ann Intern Med. 2019 Jan 15. pii: 2720956. doi: 10.7326/M18-1900.
    PubMed     Abstract available


    December 2018

  50. Correction: Glycemic Targets for Older Adults With Type 2 Diabetes.
    Ann Intern Med. 2018;169:899.
    PubMed    


  51. SANTULLI G
    In diabetes with no CVD, aspirin reduced serious vascular events but increased major bleeding at 7.4 years.
    Ann Intern Med. 2018;169:JC67.
    PubMed    


    November 2018
  52. JACKSON GL, Smith VA, Edelman D, Woolson SL, et al
    Intermediate Diabetes Outcomes in Patients Managed by Physicians, Nurse Practitioners, or Physician Assistants: A Cohort Study.
    Ann Intern Med. 2018 Nov 20. pii: 2716077. doi: 10.7326/M17-1987.
    PubMed     Abstract available


  53. WHARAM JF, Lu CY, Zhang F, Callahan M, et al
    High-Deductible Insurance and Delay in Care for the Macrovascular Complications of Diabetes.
    Ann Intern Med. 2018 Nov 20. pii: 2716078. doi: 10.7326/M17-3365.
    PubMed     Abstract available



  54. The Effect of High-Deductible Insurance Plans on Diabetes Care.
    Ann Intern Med. 2018 Nov 20. pii: 2716396. doi: 10.7326/P18-0018.
    PubMed    



  55. Comparing Diabetes Outcomes for Primary Care Provided by Physicians, Nurse Practitioners, and Physician Assistants.
    Ann Intern Med. 2018 Nov 20. pii: 2715823. doi: 10.7326/P18-0017.
    PubMed    


  56. TANNER M
    Risk scores overestimated risk for CVD in newly diagnosed type 2 diabetes.
    Ann Intern Med. 2018;169:JC59.
    PubMed    


    September 2018
  57. CENTOR RM, Barry MJ
    Web Exclusive. Annals On Call - Oral Pharmacologic Therapy in Type 2 Diabetes: Choosing Therapy Wisely.
    Ann Intern Med. 2018;169:OC1.
    PubMed    


  58. HUMPHREY LL, Kansagara D, Qaseem A
    World Health Organization Guidelines on Medicines for Diabetes Treatment Intensification: Commentary From the American College of Physicians High Value Care Committee.
    Ann Intern Med. 2018 Sep 4. pii: 2698899. doi: 10.7326/M18-1148.
    PubMed    


  59. ROGLIC G, Norris SL
    Medicines for Treatment Intensification in Type 2 Diabetes and Type of Insulin in Type 1 and Type 2 Diabetes in Low-Resource Settings: Synopsis of the World Health Organization Guidelines on Second- and Third-Line Medicines and Type of Insulin for the
    Ann Intern Med. 2018 Sep 4. pii: 2698900. doi: 10.7326/M18-1149.
    PubMed     Abstract available


  60. CENTOR RM, Montori VM
    Web Exclusive. Annals On Call - Glycemic Control in Type 2 Diabetes: How Low Should We Go?
    Ann Intern Med. 2018;169:OC1.
    PubMed    


    August 2018

  61. Prevention of Diabetes With Mediterranean Diets.
    Ann Intern Med. 2018;169:271-272.
    PubMed    


  62. O'BRIEN R, Johnson E, Haneuse S, Coleman KJ, et al
    Microvascular Outcomes in Patients With Diabetes After Bariatric Surgery Versus Usual Care: A Matched Cohort Study.
    Ann Intern Med. 2018 Aug 7. pii: 2696493. doi: 10.7326/M17-2383.
    PubMed     Abstract available



  63. Outcomes of Bariatric Surgery in Patients With Diabetes.
    Ann Intern Med. 2018 Aug 7:1. doi: 10.7326/P18-0012.
    PubMed    


    July 2018
  64. EGAN AM, Montori VM
    Review: In adults with type 1 diabetes, SGLT-2 inhibitors reduce HbA1c but increase diabetic ketoacidosis.
    Ann Intern Med. 2018;169:JC3.
    PubMed    


  65. EGAN AM, Montori VM
    Review: In type 2 diabetes, SGLT-2 inhibitors or GLP-1 agonists reduce mortality vs control or DPP-4 inhibitors.
    Ann Intern Med. 2018;169:JC2.
    PubMed    


  66. MADENIDOU AV, Paschos P, Karagiannis T, Katsoula A, et al
    Comparative Benefits and Harms of Basal Insulin Analogues for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
    Ann Intern Med. 2018 Jul 10. pii: 2687651. doi: 10.7326/M18-0443.
    PubMed     Abstract available


    June 2018
  67. HIRSCH IB, Skyler JS
    Brief Commentary: Confusing Treatment Guidelines for Patients With Type 2 Diabetes.
    Ann Intern Med. 2018 Jun 26. pii: 2686099. doi: 10.7326/M18-1473.
    PubMed    


  68. SCHROEDER EB, Karter AJ
    Brief Commentary: Glycemic Targets for Older Adults With Type 2 Diabetes.
    Ann Intern Med. 2018 Jun 26. pii: 2686097. doi: 10.7326/M18-1471.
    PubMed    


  69. MILES DRB
    Brief Commentary: Social Determinants of Health and Treatment Targets for Type 2 Diabetes.
    Ann Intern Med. 2018 Jun 26. pii: 2686098. doi: 10.7326/M18-1472.
    PubMed    


  70. BURKE BV, Hedin S
    Brief Commentary: Laboratory Accuracy of Hemoglobin A1c Ranges and Treatment Targets for Patients With Type 2 Diabetes.
    Ann Intern Med. 2018 Jun 26. pii: 2686219. doi: 10.7326/M18-1482.
    PubMed    


  71. NARAYAN KMV, Jagannathan R
    Two in One: Diagnosing Type 2 Diabetes With Single-Sample Testing.
    Ann Intern Med. 2018 Jun 19. pii: 2685289. doi: 10.7326/M18-1477.
    PubMed    


  72. SELVIN E, Wang D, Lee AK, Coresh J, et al
    Identifying Trends in Undiagnosed Diabetes in U.S. Adults.
    Ann Intern Med. 2018;168:900-901.
    PubMed    


  73. PETERSEN MP, Cefalu WT
    Identifying Trends in Undiagnosed Diabetes in U.S. Adults.
    Ann Intern Med. 2018;168:900.
    PubMed    


  74. SELVIN E, Wang D, Matsushita K, Grams ME, et al
    Prognostic Implications of Single-Sample Confirmatory Testing for Undiagnosed Diabetes: A Prospective Cohort Study.
    Ann Intern Med. 2018 Jun 19. pii: 2684927. doi: 10.7326/M18-0091.
    PubMed     Abstract available


    May 2018
  75. MOIST L
    In type 2 diabetes with CVD and kidney disease, empagliflozin reduced mortality and hospitalization.
    Ann Intern Med. 2018;168:JC52.
    PubMed    


    April 2018
  76. BEKIARI E, Karagiannis T, Tsapas A
    In type 2 diabetes, weekly semaglutide reduced HbA1c and increased weight loss more than weekly exenatide ER.
    Ann Intern Med. 2018;168:JC46.
    PubMed    


  77. VIGERSKY RA
    Continuous Glucose Monitoring in Patients With Type 2 Diabetes Receiving Insulin Injections.
    Ann Intern Med. 2018;168:528.
    PubMed    


  78. BECK RW, Riddlesworth TD
    Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections.
    Ann Intern Med. 2018;168:526-527.
    PubMed    


  79. HAAK T
    Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections.
    Ann Intern Med. 2018;168:525-526.
    PubMed    


  80. CHAMBERLAIN JJ, Johnson EL, Leal S, Rhinehart AS, et al
    Cardiovascular Disease and Risk Management: Review of the American Diabetes Association Standards of Medical Care in Diabetes 2018.
    Ann Intern Med. 2018 Apr 3. pii: 2677350. doi: 10.7326/M18-0222.
    PubMed     Abstract available


    March 2018
  81. GOEL A
    Intensive weight management in primary care improved weight loss and remission of type 2 diabetes.
    Ann Intern Med. 2018;168:JC30.
    PubMed    



  82. Hemoglobin A1c Targets for Nonpregnant Adults With Type 2 Diabetes Mellitus.
    Ann Intern Med. 2018 Mar 6. pii: 2674123. doi: 10.7326/P18-0003.
    PubMed    


  83. QASEEM A, Wilt TJ, Kansagara D, Horwitch C, et al
    Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians.
    Ann Intern Med. 2018 Mar 6. pii: 2674121. doi: 10.7326/M17-0939.
    PubMed     Abstract available


    January 2018
  84. GENERE N, Montori VM
    Review: Newer second-line drugs for diabetes are not more cost-effective than sulfonylureas.
    Ann Intern Med. 2018;168:JC8.
    PubMed    


    December 2017
  85. LIPSCOMBE LL
    Exenatide did not reduce major cardiovascular outcomes in type 2 diabetes.
    Ann Intern Med. 2017;167:JC67.
    PubMed    


  86. LIPSCOMBE LL
    Liraglutide reduced a composite renal outcome at a median 4 y in patients with type 2 diabetes and high CV risk.
    Ann Intern Med. 2017;167:JC66.
    PubMed    



  87. Cost-Effectiveness of Individualized Management of Diabetes Among U.S. Adults.
    Ann Intern Med. 2017 Dec 12. pii: 2665905. doi: 10.7326/P17-9050.
    PubMed    


  88. LAITEERAPONG N, Cooper JM, Skandari MR, Clarke PM, et al
    Individualized Glycemic Control for U.S. Adults With Type 2 Diabetes: A Cost-Effectiveness Analysis.
    Ann Intern Med. 2017 Dec 12. pii: 2665902. doi: 10.7326/M17-0537.
    PubMed     Abstract available


    October 2017
  89. SELVIN E, Wang D, Lee AK, Bergenstal RM, et al
    Identifying Trends in Undiagnosed Diabetes in U.S. Adults by Using a Confirmatory Definition: A Cross-sectional Study.
    Ann Intern Med. 2017 Oct 24. doi: 10.7326/M17-1272.
    PubMed     Abstract available


  90. CONLIN PR, Colburn J, Aron D, Pries RM, et al
    Synopsis of the 2017 U.S. Department of Veterans Affairs/U.S. Department of Defense Clinical Practice Guideline: Management of Type 2 Diabetes Mellitus.
    Ann Intern Med. 2017 Oct 24. doi: 10.7326/M17-1362.
    PubMed     Abstract available


  91. PETERS AL
    Rethinking Rates of Undiagnosed Diabetes: The Value of a Confirmatory Test.
    Ann Intern Med. 2017 Oct 24. doi: 10.7326/M17-2576.
    PubMed    


  92. DASGUPTA I, Singh AK
    Review: In diabetes, intensive and standard glycemic control do not differ for end-stage kidney disease or death.
    Ann Intern Med. 2017;167:JC47.
    PubMed    


  93. MURFF HJ
    Self-monitoring of blood glucose did not improve HbA1c or QoL at 1 year in non-insulin-treated type 2 diabetes.
    Ann Intern Med. 2017;167:JC46.
    PubMed    


    September 2017
  94. CHAMBERLAIN JJ, Kalyani RR, Leal S, Rhinehart AS, et al
    Treatment of Type 1 Diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes.
    Ann Intern Med. 2017 Sep 12. doi: 10.7326/M17-1259.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: